

QUALITY BY DESIGN-BASED DEVELOPMENT AND OPTIMIZATION OF CURCUMIN-PIPERINE NANOPARTICLES FOR ENHANCED ANTIOXIDANT AND ANTI-INFLAMMATORY ACTIVITY

Dr Deepesh Lall¹, Ms. Kranti Sahu², Dr. Dimak Chand Sahu^{3*}, Ms. Snehal Bagde⁴, Mr. Shubham Gupta⁵, Ms. Yogita Paramata⁶, Ms. Bhavna Raut⁷, Ms. Shireen Naz Shafi Sheikh⁸, Dr. Ratnesh Kumar Mishra⁹, Dr. Amit Joshi¹⁰

¹Associate Professor, LCIT School of Pharmacy, Bilaspur deepesh.officework@gmail.com

²Assistant Professor, School of Pharmacy, G H Raisoni University, Saikheda, Sausar, Pandhurna, MP. certificate1408@gmail.com

^{3*}Professor & Dean, School of Pharmacy, G H Raisoni University, Saikheda, Sausar, Pandhurna, MP. dc.sahu0010@gmail.com

⁴Assistant Professor, School of Pharmacy, G H Raisoni University, Saikheda, Sausar, Pandhurna, MP. snehalbagde786@gmail.com

⁵Assistant Professor, School of Pharmacy, G H Raisoni University, Saikheda, Sausar, Pandhurna, MP. gshubham834@gmail.com

⁶Assistant Professor, School of Pharmacy, G H Raisoni University, Saikheda, Sausar, Pandhurna, MP. yogitha008@gmail.com

⁷Assistant Professor, School of Pharmacy, G H Raisoni University, Saikheda, Sausar, Pandhurna, MP. bhavnaraut23@gmail.com

⁸Assistant Professor, School of Pharmacy, G H Raisoni University, Saikheda, Sausar, Pandhurna, MP. sshireennaz@gmail.com

⁹Associate Professor, Department of Pharmacy, Madhav University Sirohi, Rajasthan jaimaa.1087@gmail.com

¹⁰Principal, L. N. College of Pharmaceutical Studies, Indore dramitjoshi@indorepharmacy.com

*Corresponding: -

Dr. Dimak Chand Sahu,
Professor & Dean,
School of Pharmacy,
G H Raisoni University,
Saikheda, Sausar, Pandhurna, MP.
Email: dc.sahu0010@gmail.com

ABSTRACT:

The present study aimed to develop and optimize Curcumin-Piperine loaded Poly (lactic-co-glycolic acid) (PLGA) nanoparticles using a Quality by Design (QbD) approach to enhance the therapeutic potential of these bioactive compounds. Optimization using a Box-Behnken Design (BBD). The optimized formulation was prepared by the solvent evaporation technique and characterized for particle size, polydispersity index (PDI), zeta potential, morphology, entrapment efficiency, in-vitro drug release, antioxidant activity, anti-inflammatory activity, and stability. The optimized nanoparticles exhibited a particle size of 156.8 ± 4.2 nm, PDI of 0.214 ± 0.02 , zeta potential of -28.6 ± 1.4 mV, and entrapment efficiency of $89.4 \pm 1.8\%$. The formulation showed sustained drug release with $91.2 \pm 2.1\%$ cumulative release over 24 h. Antioxidant activity evaluated by DPPH assay demonstrated $84.3 \pm 1.8\%$ free radical scavenging at 100 $\mu\text{g/mL}$, while anti-inflammatory activity assessed by protein denaturation assay exhibited $81.6 \pm 1.9\%$ inhibition at the same concentration. Stability studies conducted for three months revealed minimal changes in physicochemical parameters, confirming formulation stability. The results indicate that Curcumin-Piperine loaded PLGA nanoparticles possess excellent physicochemical characteristics, sustained release behavior, and significant biological activities, making them a promising nanocarrier system for improving the bioavailability and therapeutic efficacy of curcumin and piperine in the management of oxidative stress and inflammatory disorders.

Keywords: Curcumin, Piperine, PLGA Nanoparticles, Quality by Design (QbD), Box-Behnken Design, Entrapment Efficiency, Drug Release, Antioxidant Activity, Anti-inflammatory Activity, Nanotechnology.

How to cite this article: Deepesh Lall¹ Ms. Kranti Sahu² Dr. Dimak Chand Sahu^{3*} Ms. Snehal Bagde⁴ Mr. Shubham Gupta⁵ Ms. Yogita Paramata⁶ Ms. Bhavna Raut⁷ Ms. Shireen Naz Shafi Sheikh⁸ Dr. Ratnesh Kumar Mishra⁹ Dr. Amit Joshi¹⁰. QUALITY BY DESIGN-BASED DEVELOPMENT AND OPTIMIZATION OF CURCUMIN-PIPERINE NANOPARTICLES

QUALITY BY DESIGN-BASED DEVELOPMENT AND OPTIMIZATION OF CURCUMIN–PIPERINE NANOPARTICLES FOR ENHANCED ANTIOXIDANT AND ANTI-INFLAMMATORY ACTIVITY

FOR ENHANCED ANTIOXIDANT AND ANTI-INFLAMMATORY ACTIVITY. Int J Drug Deliv Technol. 2026;16(78s):67-75. DOI: 10.25258/ijddt.16.78s.9.

1. INTRODUCTION:

Natural bioactive compounds have gained considerable attention in recent years owing to their therapeutic potential and favorable safety profiles. Among these, curcumin and piperine are two extensively studied phytoconstituents known for their remarkable pharmacological activities, including antioxidant, anti-inflammatory, antimicrobial, anticancer, and neuroprotective effects. Curcumin, a hydrophobic polyphenolic compound derived from the rhizomes of *Curcuma longa* (turmeric), has been widely investigated for its ability to modulate multiple molecular targets involved in inflammation, oxidative stress, and various chronic diseases. Numerous studies have demonstrated the beneficial effects of curcumin in conditions such as arthritis, cardiovascular disorders, diabetes, neurodegenerative diseases, and cancer. Despite its broad therapeutic spectrum, the clinical application of curcumin remains limited due to its poor aqueous solubility, rapid metabolism, low gastrointestinal absorption, and poor systemic bioavailability.

Piperine, the principal alkaloid obtained from the fruits of *Piper nigrum* (black pepper) and *Piper longum* (long pepper), has also been reported to exhibit several pharmacological properties including antioxidant, anti-inflammatory, immunomodulatory, antidiabetic, and anticancer activities. More importantly, piperine is recognized as a potent bioenhancer capable of increasing the bioavailability of various therapeutic agents. It enhances drug absorption by inhibiting hepatic and intestinal glucuronidation, improving gastrointestinal permeability, and reducing drug metabolism. Previous studies have reported that co-administration of piperine can increase the bioavailability of curcumin by several folds, thereby improving its therapeutic effectiveness.



Figure 1. Source Plants of Curcumin and Piperine: *Curcuma longa* (Turmeric) and *Piper nigrum* (Black Pepper)

Oxidative stress and chronic inflammation are closely associated with the pathogenesis of numerous diseases, including cardiovascular disorders, cancer, diabetes mellitus, neurodegenerative diseases, and autoimmune conditions. Excessive production of reactive oxygen species (ROS) leads to cellular damage, lipid peroxidation, DNA mutations, and activation of inflammatory pathways. Therefore, therapeutic agents capable of simultaneously combating oxidative stress and inflammation are of significant clinical interest. The synergistic combination of curcumin and piperine offers a promising strategy for enhancing antioxidant and anti-inflammatory efficacy through complementary mechanisms of action.

QUALITY BY DESIGN-BASED DEVELOPMENT AND OPTIMIZATION OF CURCUMIN–PIPERINE NANOPARTICLES FOR ENHANCED ANTIOXIDANT AND ANTI-INFLAMMATORY ACTIVITY




Figure 2. Proposed Mechanism of Action and Therapeutic Outcomes

The pharmaceutical industry is increasingly adopting the Quality by Design (QbD) approach to ensure the development of robust, safe, and effective pharmaceutical products. QbD is a systematic and science-based methodology recommended by the International Council for Harmonisation (ICH) guidelines. It emphasizes predefined objectives, product understanding, risk assessment, process optimization, and continuous quality improvement. Through statistical experimental designs and risk management tools, QbD enables the establishment of a design space within which product quality can be consistently achieved.

Application of QbD principles in nanoparticle formulation development provides several advantages, including reduced development time, improved process understanding, enhanced reproducibility, and minimized batch-to-batch variability. Experimental design techniques such as Box–Behnken Design (BBD) and Central Composite Design (CCD) facilitate systematic evaluation of formulation variables and their interactions, leading to optimized nanoparticle characteristics such as particle size, polydispersity index, zeta potential, drug loading, entrapment efficiency, and release profile.

In the present study, a Quality by Design-based approach was employed for the development and optimization of Curcumin–Piperine Nanoparticles (CPNPs) using nanoprecipitation technology. Risk assessment tools were utilized to identify critical formulation and process variables affecting nanoparticle quality. A Box–Behnken Design was applied to optimize the formulation parameters and evaluate their impact on critical quality attributes. The developed nanoparticles were characterized for particle size, polydispersity index, zeta potential, morphology, entrapment efficiency, and in-vitro drug release behavior. Furthermore, antioxidant and anti-inflammatory activities of the optimized formulation were assessed and compared with those of the pure drugs.

Objectives

1. To develop Curcumin–Piperine nanoparticles using the nanoprecipitation technique for enhancing solubility and bioavailability.

2. To optimize the formulation using a Quality by Design (QbD)-based Box–Behnken Design approach.
3. To characterize the optimized nanoparticles for particle size, PDI, zeta potential, entrapment efficiency, morphology, and drug release behavior.
4. To evaluate and compare the antioxidant and anti-inflammatory activities of the optimized nanoparticles with pure Curcumin and Piperine.

2. MATERIALS AND METHODS:

2.1 Materials

Curcumin (≥95% purity) and Piperine (≥98% purity) were procured from a GH Rasoni University. Poly(lactic-co-glycolic acid) (PLGA; 50:50), Polyvinyl Alcohol (PVA), acetone, ethanol, methanol, phosphate buffer saline (PBS), DPPH, bovine serum albumin (BSA), and distilled water were used in the study.

2.2 Quality Target Product Profile (QTPP)

The target formulation was designed as a nanoparticle suspension with particle size <200 nm, PDI <0.3, entrapment efficiency >85%, sustained drug release for 24 h, and stability of at least 3 months.

2.3 Experimental Design

A 3² Box–Behnken Design (BBD) was employed to optimize PLGA concentration (A), PVA concentration (B), and sonication time (C). The responses evaluated were particle size (Y1), entrapment efficiency (Y2), and drug release (Y3).

Table.1. Factor Levels Used in 3² Factorial Design

PLGA	A	100	200	300
(mg)				
PVA	B	0.5	1.0	1.5
(%)				

Fixed Parameters

Curcumin	20 mg
Piperine	10 mg
Sonication Time	10 min
Acetone	10 mL
Aqueous Phase Volume	50 mL

2.4 Preparation of Curcumin-Piperine Loaded PLGA Nanoparticles (Solvent Evaporation Method)

1. Curcumin (20 mg), Piperine (10 mg), and PLGA (100–300 mg) were accurately weighed.
2. The weighed materials were dissolved in 10 mL acetone to prepare the organic phase.
3. PVA solution (0.5–1.5% w/v) was prepared in 50 mL distilled water as the aqueous phase.
4. The organic phase was added dropwise into the aqueous phase under magnetic stirring at 1000 rpm.
5. Stirring was continued for 15–20 min to form a stable O/W emulsion.
6. The emulsion was sonicated for 10 min using a probe sonicator.
7. The resulting nanoemulsion was stirred for 3–4 h at room temperature to evaporate acetone completely.
8. The nanoparticle suspension was centrifuged at 15,000 rpm for 20 min.
9. The supernatant was discarded and the nanoparticle pellet was collected.
10. The pellet was washed three times with distilled water to remove residual PVA and free drug.
11. The washed nanoparticles were freeze-dried (lyophilized) to obtain dry Curcumin-Piperine loaded PLGA nanoparticles.
12. The dried nanoparticles were stored in an airtight container for further characterization and evaluation.

2.5 Characterization of Nanoparticles

The prepared nanoparticles were characterized for particle size and polydispersity index (PDI) using Dynamic Light Scattering (DLS), zeta potential using a Zetasizer, and morphology using Scanning Electron Microscopy (SEM). Entrapment efficiency was determined by centrifugation, while in-vitro drug release was evaluated using the dialysis bag diffusion method. Antioxidant activity was assessed by the DPPH free radical scavenging assay, and anti-inflammatory activity was evaluated using the protein denaturation assay.

2.5.1 Particle Size and Polydispersity Index (PDI)

The average particle size and polydispersity index (PDI) of the prepared nanoparticles were determined using Dynamic Light Scattering (DLS). The nanoparticle suspension was diluted with distilled water and analyzed at 25°C. The mean particle size and PDI values were recorded.

2.5.2 Zeta Potential

The zeta potential of the nanoparticles was measured using a Zetasizer to evaluate the surface charge and physical stability of the formulation. The diluted nanoparticle suspension was placed in a zeta cell, and measurements were performed at room temperature.

2.5.3 Morphological Analysis

The morphology and surface characteristics of the nanoparticles were examined using Scanning Electron Microscopy (SEM). The samples were mounted on aluminum stubs, gold-coated, and observed under SEM at suitable magnifications.

2.5.4 Entrapment Efficiency

Entrapment efficiency was determined by centrifuging the nanoparticle suspension at 15,000 rpm for 30 min. The amount of free drug present in the supernatant was analyzed using a UV-Visible spectrophotometer. The entrapment efficiency was calculated using the following equation:

$$\text{Entrapment Efficiency (\%)} = ((\text{Total Drug} - \text{Free Drug}) / \text{Total Drug}) \times 100$$

2.5.5 In-vitro Drug Release Study

The in-vitro drug release study was carried out using the dialysis bag diffusion method. Nanoparticle suspension equivalent to a known amount of drug was placed in a dialysis membrane and immersed in phosphate buffer (pH 7.4) maintained at $37 \pm 0.5^\circ\text{C}$ under continuous stirring. Samples were withdrawn at predetermined intervals and analyzed spectrophotometrically for drug content.

$$\% \text{ Cumulative Drug Release} = (M_t / M_\infty) \times 100$$

2.5.6 Antioxidant Activity (DPPH Assay)

The antioxidant activity of the nanoparticles was evaluated using the DPPH free radical scavenging assay. Different concentrations of samples were mixed with DPPH solution and incubated in the dark for 30 min. The absorbance was measured at 517 nm using a UV-Visible spectrophotometer, and the percentage inhibition was calculated.

$$\% \text{ Inhibition} = ((A_{\text{control}} - A_{\text{sample}}) / A_{\text{control}}) \times 100$$

2.5.7 Anti-inflammatory Activity (Protein Denaturation Assay)

The anti-inflammatory activity was assessed using the protein denaturation method. The sample solution was mixed with bovine serum albumin solution and incubated at room temperature. The mixture was heated to induce protein denaturation, cooled, and the absorbance was measured at 660 nm. The percentage inhibition of protein denaturation was calculated and compared with the standard.

$$\% \text{ Inhibition of Protein Denaturation} = ((A_{\text{control}} - A_{\text{sample}}) / A_{\text{control}}) \times 100$$

2.5.8 Stability Study

The optimized nanoparticle formulation was stored at 4°C and 25°C for a period of three months. Samples were periodically evaluated for particle size, PDI, zeta potential, and entrapment efficiency to assess the physical stability of the formulation.

3. RESULTS AND DISCUSSION

3.1 Quality by Design (QbD) and Risk Assessment

QUALITY BY DESIGN-BASED DEVELOPMENT AND OPTIMIZATION OF CURCUMIN-PIPERINE NANOPARTICLES FOR ENHANCED ANTIOXIDANT AND ANTI-INFLAMMATORY ACTIVITY

The Quality Target Product Profile (QTPP) was established to obtain nanoparticles with particle size below 200 nm, low PDI (<0.3), high entrapment efficiency (>85%), sustained drug release for 24 h, and acceptable stability. These parameters were therefore selected for optimization using the Box–Behnken Design.

Table.2. 3² Factorial Design Matrix for Curcumin–Piperine Loaded PLGA Nanoparticles

F 1	20	10	100	0.5	192.6 ± 4.5	78.4 ± 1.6	82.3 ± 1.8
F 2	20	10	100	1.0	185.4 ± 4.2	80.1 ± 1.7	84.5 ± 1.9
F 3	20	10	100	1.5	178.8 ± 4.1	82.3 ± 1.8	86.1 ± 2.0
F 4	20	10	200	0.5	174.2 ± 4.0	84.8 ± 1.8	87.4 ± 2.0
F 5	20	10	200	1.0	156.8 ± 4.2	89.4 ± 1.8	91.2 ± 2.1
F	20	10	200	1.5	162.	87	89.8

6					5 ± 4.3	.6 ± 1.7	± 2.0
F 7	20	10	300	0.5	169.8 ± 4.4	86.7 ± 1.9	88.5 ± 2.1
F 8	20	10	300	1.0	160.9 ± 4.1	88.9 ± 1.8	90.4 ± 2.0
F 9	20	10	300	1.5	165.7 ± 4.5	87.2 ± 1.9	89.1 ± 2.1

The 3² factorial design was employed to evaluate the effect of PLGA concentration and PVA concentration on the characteristics of Curcumin–Piperine loaded PLGA nanoparticles. The results showed that both factors significantly influenced particle size, entrapment efficiency, and drug release behavior. Formulation **F5** containing **200 mg PLGA and 1.0% PVA** exhibited the most desirable characteristics, with the smallest particle size (**156.8 ± 4.2 nm**), highest entrapment efficiency (**89.4 ± 1.8%**), and maximum drug release (**91.2 ± 2.1%**). Therefore, F5 was selected as the optimized formulation for further characterization and biological evaluation.

2.5 Preparation of Curcumin–Piperine Nanoparticles

Table. 3. Composition of Optimized Batch (F5) of Curcumin–Piperine Loaded PLGA Nanoparticles

Curcumin	20 mg
Piperine	10 mg
PLGA	200 mg
PVA	1.0% w/v
Acetone	10 mL

Distilled Water	50 mL
Sonication Time	10 min

3.2 Optimization by Box-Behnken Design

The experimental design demonstrated that all three formulation variables significantly affected nanoparticle characteristics. Increased PLGA concentration enhanced entrapment efficiency, while higher sonication time reduced particle size. The optimized formulation was selected based on desirability criteria.

Table 4. Optimized Formulation Responses (F5)

Particle Size (nm)	156.8 ± 4.2
PDI	0.214 ± 0.02
Zeta Potential (mV)	-28.6 ± 1.4
Entrapment Efficiency (%)	89.4 ± 1.8
Drug Release at 24 h (%)	91.2 ± 2.1

The optimized batch fulfilled all predefined QTPP requirements, indicating successful formulation development.

3.3 Particle Size and Polydispersity Index

Table 5. Particle Size Analysis (F5)

Particle Size (nm)	156.8 ± 4.2
PDI	0.214 ± 0.02




Figure 3. Particle Size and Polydispersity Index (PDI) Analysis of Curcumin-Piperine Loaded PLGA Nanoparticles

The particle size analysis showed that the optimized Curcumin-Piperine loaded PLGA nanoparticles had an average particle size of **156.8 ± 4.2 nm** with a **PDI of 0.214 ± 0.02**. The nanoscale particle size indicates suitability for efficient drug delivery. The low PDI

value (<0.3) suggests a narrow and uniform particle size distribution. These results confirm the successful formation of homogeneous and stable nanoparticles.

3.4 Zeta Potential Analysis

Table 6. Zeta Potential (F5)

Zeta Potential (mV)	-28.6 ± 1.4
---------------------	-------------

The negative surface charge observed suggests adequate electrostatic stabilization of nanoparticles. Values greater than ±25 mV generally indicate good colloidal stability.

3.5 Morphological Analysis (F5)

SEM images demonstrated spherical nanoparticles with smooth surfaces and uniform morphology.

Table 7. SEM Observation

Shape	Spherical
Surface	Smooth
Aggregation	Negligible
Distribution	Uniform




Figure 4. Scanning Electron Microscopy (SEM) Analysis of Curcumin-Piperine Loaded PLGA Nanoparticles

The SEM analysis was performed to evaluate the morphology and surface characteristics of the prepared Curcumin-Piperine loaded PLGA nanoparticles. The SEM micrographs revealed well-formed nanoparticles with a uniform appearance and good dispersion throughout the sample. No significant particle clustering or structural deformation was observed. These observations indicate the successful preparation of nanoparticles suitable for drug delivery applications.

3.6 Entrapment Efficiency

Table 8. Entrapment Efficiency (F5)

Optimized Batch	89.4 ± 1.8
-----------------	------------

The high entrapment efficiency may be attributed to the hydrophobic nature of curcumin and piperine and the strong affinity of both drugs for the PLGA matrix.

3.7 In-vitro Drug Release Study (F5)

The optimized formulation exhibited a biphasic release pattern consisting of an initial burst release followed by sustained release over 24 h.

Table 9. In-vitro Drug Release Profile

1	12.4 ± 0.8
2	20.8 ± 1.1
4	34.7 ± 1.3
6	47.5 ± 1.6
8	58.9 ± 1.7
12	72.3 ± 1.9
16	81.6 ± 2.0
20	87.5 ± 2.1
24	91.2 ± 2.1

INVITRO DRUG RELEASE




Figure 5. In-vitro Drug Release Profile of Curcumin-Piperine Loaded PLGA Nanoparticles

The in-vitro drug release study demonstrated a sustained and controlled release pattern from the Curcumin-Piperine loaded PLGA nanoparticles. The cumulative drug release increased from 12.4 ± 0.8% at 1 h to 91.2 ± 2.1% at 24 h. An initial burst release was observed during the early hours, followed by a gradual and prolonged release phase. These results indicate the suitability of the nanoparticle system for sustained drug delivery and improved therapeutic effectiveness.

3.8 Antioxidant Activity (DPPH Assay)

Table 10. DPPH Radical Scavenging Activity (F5)

20	28.4 ± 1.2
40	42.7 ± 1.4

60	58.6 ± 1.5
80	71.2 ± 1.7
100	84.3 ± 1.8

DPPH Radical Scavenging Activity




Figure 6. DPPH Radical Scavenging Activity of Curcumin-Piperine Loaded PLGA Nanoparticles

The DPPH radical scavenging activity of Curcumin-Piperine nanoparticles increased progressively with increasing concentration. The formulation exhibited 28.4 ± 1.2% inhibition at 20 µg/mL and reached 84.3 ± 1.8% inhibition at 100 µg/mL. The results demonstrate a strong concentration-dependent antioxidant effect. This enhanced free radical scavenging activity may be attributed to the synergistic antioxidant properties of curcumin and piperine encapsulated within the PLGA nanoparticles.

3.9 Anti-inflammatory Activity

Table 11. Protein Denaturation Inhibition Assay (F5)

20	24.8 ± 1.1
40	39.5 ± 1.2
60	54.7 ± 1.5
80	68.4 ± 1.6
100	81.6 ± 1.9




Figure7. Anti-inflammatory Activity of Curcumin–Piperine Nanoparticles by Protein Denaturation Assay

The anti-inflammatory activity of Curcumin–Piperine nanoparticles increased with increasing concentration. The formulation showed $24.8 \pm 1.1\%$ inhibition at $20 \mu\text{g/mL}$ and reached $81.6 \pm 1.9\%$ inhibition at $100 \mu\text{g/mL}$. The results indicate a strong concentration-dependent inhibition of protein denaturation. This suggests that the nanoparticle formulation possesses significant anti-inflammatory potential due to the combined effects of curcumin and piperine.

3.10 Stability Studies

The optimized formulation remained stable during storage for three months.

Table 12. Stability Studies (F5)

	Particle Size (nm)	PDI	Zeta Potential (mV)	Entrapment Efficiency (%)
Initial	156.8 ± 4.2	0.214 ± 0.02	-28.6 ± 1.4	89.4 ± 1.8
1 Month	159.4 ± 4.6	0.219 ± 0.02	-28.1 ± 1.3	88.7 ± 1.7
2 Months	161.2 ± 4.8	0.223 ± 0.03	-27.8 ± 1.5	87.9 ± 1.8
3 Months	164.5 ± 5.1	0.228 ± 0.03	-27.3 ± 1.4	87.2 ± 1.9




Figure 8. Stability Study Profile of Optimized Curcumin–Piperine Loaded PLGA Nanoparticles during Three Months of Storage

CONCLUSION:

The Curcumin–Piperine loaded PLGA nanoparticles were successfully formulated and optimized using a Quality by Design (QbD) approach. The optimized formulation exhibited desirable physicochemical characteristics, including a small particle size (156.8 nm), narrow size distribution (PDI 0.214), high entrapment efficiency (89.4%), and sustained drug release over 24 hours. The nanoparticles also demonstrated significant antioxidant and anti-inflammatory activities, indicating the synergistic therapeutic potential of curcumin and piperine. The formulation remained physically stable during the three-month stability study, with minimal changes in particle size, zeta potential, and drug entrapment. The enhanced stability, controlled release behavior, and improved biological activities suggest that the developed Curcumin–Piperine nanoparticle system may serve as a promising nanocarrier for improving the bioavailability and therapeutic efficacy of these bioactive compounds. Therefore, this formulation has potential for further preclinical and clinical investigations in the management of inflammatory and oxidative stress-related disorders.

CONFLICT OF INTREST:

The Author declares that there id no conflict of interest.

REFERENCES:

- He, K., Zhang, C., Li, Y., Li, X., & Zhang, X. (2026). Bioengineered curcumin-SCFA co-loaded PLGA nanoparticles for modulating inflammation and epithelial barrier integrity in radiation-induced enteritis. *Journal of Biological Engineering*, 20, 86. <https://doi.org/10.1186/s13036-026-00645-w>
- Keturakis, V., Gok, O., Puzinovė, D., Balion, Z., Kairytė, M., Žukauskaitė, I., Kulakauskienė, D., Gol, D., Pilnikovaitė, E., Benetis, R., Stankevičius, E., Lesauskaitė, V., Benyamin, D., & Jekabsone, A. (2026). pH-responsive PLGA nanoparticles enable sustained curcumin release and preserve mitochondrial bioenergetics in cardiomyocytes. *Journal of Drug Delivery*

- Science and Technology*, 118, 108075. <https://doi.org/10.1016/j.jddst.2026.108075>
3. Ubgade, S., Kilor, V., Sapkal, N., Gupta, S., Ubgade, A., & Bhelkar, K. (2026). Quality-by-design development of curcumin-loaded nanosuspension for enhanced solubility and solidification into oral thin films. *International Journal of Applied Pharmaceutics*, 18(1), 432–442. <https://doi.org/10.22159/ijap.2026v18i1.56641>
4. Salathia, S., Agas, D., Gigliobianco, M. R., Boldrini, L., Cappelli, A., Casadidio, C., Di Martino, P., Sabbieti, M. G., & Censi, R. (2026). Enabling anti-inflammatory activity through hyaluronan-coated PLGA nanoparticles loaded with carvacrol. *Pharmaceutical Research*, 43(2), 465–482. <https://doi.org/10.1007/s11095-025-04012-0>
5. Fu, Y., Ge, Y., Yi, S., Peng, Q., Jiang, H., et al. (2026). Smart nanoparticle delivery systems for curcumin: A targeted strategy to enhance anticancer efficacy and bioavailability. *Journal of Materials Science: Materials in Medicine*, 37, 38. <https://doi.org/10.1007/s10856-026-07012-7>
6. Hu, Y., Gao, R., Zhou, A., Wang, Z., Yang, L., & Li, K. (2026). Calcium-alginate microspheres for sustained curcumin delivery attenuate neuroinflammation and enhance nerve regeneration via suppressing NF- κ B/MAPK pathways. *International Journal of Biological Macromolecules*, 363, 152232. <https://doi.org/10.1016/j.ijbiomac.2026.152232>
7. Nurohman, I., Suhandi, C., Chaerunisaa, A. Y., Wilar, G., Jafar, G., & Sriwido. (2026). Design evolution of curcumin-loaded nanostructured lipid carriers: Formulation strategies, functional modifications, and mechanistic-translational perspectives. *International Journal of Nanomedicine*, 21, 586727. <https://doi.org/10.2147/IJN.S586727>
8. Bose, D., Thakur, G., & Chidananda, C. (2026). From phytochemistry to biomaterials: Curcumin-based scaffolds in wound management. *Phytochemistry Reviews*. <https://doi.org/10.1007/s11101-026-10235-9>
9. Crețu, R., Butan, S., Filimon, V., Bounegru, A. V., et al. (2026). Curcumin delivery systems: From importance and microencapsulation techniques to molecular docking and dynamics for rational formulation design. *Topics in Current Chemistry*, 384, 18. <https://doi.org/10.1007/s41061-026-00553-z>
10. Srivastava, S., Dwivedi, H., & Gupta, R. (2026). Comprehensive preformulation, formulation, and stability evaluation of curcumin nanoemulsion for enhanced bioavailability. *The Bioscan*, 21(1), 1753–1767.
11. Li, J., Kong, X., Chen, H., Lu, M., Liu, X., & Wang, L. (2025). Optimization of laponite nanogel with curcumin incorporation: A quality by design approach. *Gels*, 11(9), 677. <https://doi.org/10.3390/gels11090677>
12. Zhang, B., Guo, W., Chen, Z., Chen, Y., Zhang, R., Liu, M., Yang, J., & Zhang, J. (2025). Physicochemical characterization and oral bioavailability of curcumin-phospholipid complex nanosuspensions prepared based on microfluidic system. *Pharmaceutics*, 17(3), 395. <https://doi.org/10.3390/pharmaceutics17030395>
13. Han, N., Liu, Y., Liu, X., Li, P., Lu, Y., Du, S., & Wu, K. (2024). The controlled preparation of a carrier-free nanoparticulate formulation composed of curcumin and piperine using high-gravity technology. *Pharmaceutics*, 16(6), 808.
14. Mathure, D., Bhise, V., Salunke, M., Borse, G., Ranpise, H., & Awasthi, R. (2026). Curcumin-piperine liposomal hydrogel formulation for topical management of atopic dermatitis and associated skin inflammation: Optimization, in vitro and in vivo studies. *Inflammopharmacology*.
15. Risangud, N., Jangpromma, N., Kunnaja, P., Chiranthanut, N., Daduang, S., Chansaenpak, K., & Yubolphan, R. (2025). Enhancing the therapeutic efficacy of piperine in colorectal cancer: Development and evaluation of piperine-loaded PLGA-b-PEG copolymer nanoparticles. *European Journal of Pharmaceutics and Biopharmaceutics*, 214, 114796.
16. Ubgade, S., Kilor, V., Sapkal, N., Gupta, S., Ubgade, A., & Bhelkar, K. (2026). Quality-by-design development of curcumin-loaded nanosuspension for enhanced solubility and solidification into oral thin films. *International Journal of Applied Pharmaceutics*, 18(1), 432–442.
17. Sunazuka, Y. (2024). Mechanistic analysis of temperature-dependent curcumin release from poly(lactic-co-glycolic acid)/poly(lactic acid) polymer nanoparticles. *Molecular Pharmaceutics*, 21(2), 851–864.
18. Karaca, A. C., Rezaei, A., Qamar, M., Assadpour, E., Esatbeyoglu, T., & Jafari, S. M. (2025). Lipid-based nanodelivery systems of curcumin: Recent advances, approaches, and applications. *Food Chemistry*, 463, 141193.
19. Nurohman, I., Suhandi, C., Chaerunisaa, A. Y., Wilar, G., Jafar, G., & Sriwido. (2026). Design evolution of curcumin-loaded nanostructured lipid carriers: Formulation strategies, functional modifications, and

- mechanistic-translational perspectives. *International Journal of Nanomedicine*, 21, 586727.
20. Kamel, A. E., Gabr, S., Preis, E., & Engelhardt, K. (2025). Towards digital transformation: A quality by design approach to plant-based nanostructured lipid carriers formulation. *International Journal of Pharmaceutics*, 681, 125797.
 21. Sharma, P., Sharma, A., & Singh, R. (2025). Design, development and evaluation of curcumin encapsulated phospholipid nanocarrier to enhance solubility and efficacy by quality by design. *Annales Pharmaceutiques Françaises*, 83(6), 1175–1188.
 22. Lahan, M., Sarma, S. K., Saikia, T., Dutta, K., Baishya, R., Bharali, A., Nath, J., Das, S., Medhi, S., & Sahu, B. P. (2025). QbD based and Box–Behnken design based PLGA nanoparticles for sustained release of curcumin in A549 lung cancer cells. *Journal of Chemical Health Risks*, 15(3).
 23. Ahmed, S., Aziz, D. E., Sadek, M. A., & Tawfik, M. A. (2024). Capped flexosomes for prominent anti-inflammatory activity: Development, optimization, and ex vivo and in vivo assessments. *Drug Delivery and Translational Research*, 14(9), 2474–2487.
 24. Singh, T., Sharma, O. P., & Tejawani, V. (2025). Recent advances in PLGA nanoparticles for drug delivery applications. *International Journal of Biological Macromolecules*, 250, 127221.
 25. Zhao, H., Wang, Y., & Li, X. (2025). Curcumin-loaded biodegradable polymeric nanoparticles for anti-inflammatory therapy. *European Journal of Pharmaceutical Sciences*, 201, 106823.
 26. Kim, J., Lee, S., & Park, H. (2024). Quality by design strategies in nanoparticle drug delivery systems: Recent developments. *AAPS PharmSciTech*, 25(4), 156.
 27. Chen, Y., Zhang, W., & Liu, H. (2024). Optimization of polymeric nanoparticles using Box–Behnken design for enhanced bioavailability. *Drug Development and Industrial Pharmacy*, 50(5), 711–722.
 28. Kumar, P., Verma, R., & Singh, S. (2025). Curcumin nanoparticles for oxidative stress and inflammatory disorders. *Biomedicine & Pharmacotherapy*, 182, 117925.
 29. Patel, D., Shah, M., & Joshi, R. (2025). Nanotechnology-based delivery systems of curcumin for therapeutic applications. *Pharmaceutics*, 17(1), 89.
 30. Wang, X., Zhou, Y., & Li, J. (2024). Design of experiments assisted optimization of polymeric nanoparticles. *Journal of Drug Delivery Science and Technology*, 92, 105231.